GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M

GoodRx Holdings, Inc.

2024-Q3 EPS reported $0.02 revenue$593,741,000

Revenue and Adjusted Revenue both $195.3 million for Q3 2024.
Net income of $4.0 million (2.0% margin); Adjusted Net Income $31.9 million (16.4% margin).
Adjusted EBITDA $65.0 million (33.3% margin); operating cash flow $86.9 million.
Exited Q3 with over 7 million consumers of prescription-related offerings.
Expects ~20% YoY growth in pharma manufacturer solutions for Q4 2024 and 20%+ for FY 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.